Clinical Trials Browser

OTHER × Prostatic Neoplasms × daratumumab × Clear all

NCT03035357 2024-05-03

Neoadjuvant Listeria or Daratumumab in Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT03177460 2024-05-03

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms